Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Clinical trial NCT03623243 · COMPLETED

Trial details

NCT number: NCT03623243
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis Relapsing Multiple Sclerosis Advancing Multiple Sclerosis

Start date: 2019-02-14
Primary completion: 2022-07-06
Enrollment: 185

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.